Avsar.

Healthcare · Pharmaceuticals

Orchid Pharma Ltd (ORCHPHARMA)

₹839.45

Mkt cap
₹5,350 Cr
P/E ratio
296.00
P/B
2.80
Div yield
0.00%
ROE
1.49%
ROCE
1.86%
EPS (TTM)
₹2.84
Book value
₹300
52W range
480–1,144
Sector
Healthcare

Price history

Previous close

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

NSE ORCHPHARMABSE 524372
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−26.59% from high
₹839
₹480+74.89% from low₹1,144
Current
₹839.45
Prev close
₹891.00
Day
−5.79%
Price performance
1D
−5.79%
1W
+1.96%
1M
−17.29%
3M
−16.08%
6M
+36.97%
1Y
+15.70%
YTD
+5.64%

Financials

Revenue, profit & margin
P/E ratio
296.0×
ORCHPHARMA is 758% above the sector median of 34.5×
ORCHPHARMA296.0×
Sector median34.5×
 Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales182.92198.76220.59217.10244.41222.70217.34237.48263.19193.52207.27368.33304.17
Expenses160.78175.46185.21188.19211.92192.36190.97209.49268.84194.99205.71338.17290.17
Operating Profit22.1423.3035.3828.9132.4930.3426.3727.99-5.65-1.471.5630.1614.00
OPM %12.10%11.72%16.04%13.32%13.29%13.62%12.13%11.79%-2.15%-0.76%0.75%8.19%4.60%
Other Income1.898.367.6213.367.577.528.493.9011.5710.77-1.507.551.83
Interest5.553.803.543.473.503.333.803.922.283.733.181.962.23
Depreciation7.717.849.278.428.448.638.618.8710.538.909.0310.9010.95
Profit before tax10.7720.0230.1930.3828.1225.9022.4519.10-6.89-3.33-12.1524.852.65
Tax %0.00%0.00%0.00%-10.27%-0.53%0.00%0.00%-0.21%0.00%0.00%0.00%0.00%2.64%
Net Profit9.4019.8029.4332.9629.3527.2420.7822.29-5.69-5.72-12.6125.843.22
EPS in Rs1.853.905.806.505.795.374.104.39-1.12-1.13-2.495.090.63
Raw PDF

Earnings

Results dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −4.52% · closed higher next day 0 of last 2
 Q4FY26†Q1FY27
Broadcast14 Aug '26◦14 Aug '26◦
Earnings day−4.52%−4.52%
+1 day−7.31%−7.31%
+5 days−0.72%−0.72%
+15 days−9.42%−9.42%
+30 days−2.94%−2.94%
FilingPDFXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Sep 2026
74.45%Promoter
Promoters74.45%4.61
FIIs0.93%0.13
DIIs17.44%3.31
Public7.17%1.45
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,761.0033.454,22,5230.91%2,901+5.95%15,300+10.46%20.53%
Divi's Lab.₹9,664.0086.112,56,5490.31%902+65.50%3,080+27.80%21.97%
Torrent Pharma.₹4,580.0080.241,74,2080.83%534−10.03%4,979+50.79%15.19%
Laurus Labs₹2,244.0090.491,21,2460.09%436+126.43%2,206+33.44%17.76%
Zydus Lifesci.₹1,184.4024.271,18,1440.08%990−35.09%8,017+21.96%21.14%
Dr Reddy's Labs₹1,345.0040.101,12,2650.59%913−31.35%8,698−1.48%13.04%
Cipla₹1,358.0035.331,09,7090.96%852−35.05%7,404−2.44%15.49%
Orchid Pharma₹893.40296.245,3500.00%3+156.59%304+15.57%1.86%
Median: 159 Co.₹439.1034.491,9340.08%14+22.88%170+18.91%15.11%

Filings

Annual reports15
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023Annual Report 2022Annual Report 2021Annual Report 2020Annual Report 2019Annual Report 2018Annual Report 2017Annual Report 2016Annual Report 2015Annual Report 2013Annual Report 2013Annual Report 2012
Concall transcripts48
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024RECMay 2024TranscriptFeb 2024
Credit ratings6
Rating update 8 AprcareRating update 7 Aug 2025careRating update 10 Mar 2025careRating update 15 Dec 2023careRating update 30 Nov 2023careRating update 10 Feb 2023care
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 24 Oct - Orchid Pharma signs Latin America licensing and supply deal for Exblifep across nine markets; potential USD 80 million.Announcement under Regulation 30 (LODR)-Raising of Funds 20 Oct - Board approved enabling resolution on Oct. 20, 2026 to raise up to Rs 600 crore.Board Meeting Outcome for Outcome Of Board Meeting 20 Oct - Board approved enabling resolution to raise up to Rs 600 crore via equity or other securities.Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On October 20, 2026. 15 Oct - Board meets October 20, 2026 to consider equity, debt or warrant-based fund raising options.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Oct - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018